IQVIA (NYSE:IQV) Stock Moved Down to “Hold” by Wall Street Zen

Wall Street Zen lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Several other research analysts also recently commented on the company. Evercore lifted their target price on IQVIA from $275.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Royal Bank Of Canada increased their price target on IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. BMO Capital Markets raised their price target on IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Weiss Ratings cut shares of IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research report on Wednesday, October 28th. Finally, Robert W. Baird lifted their price objective on shares of IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $294.21.

View Our Latest Stock Analysis on IQVIA

IQVIA Stock Down 1.9%

Shares of IQV stock opened at $245.68 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. The firm’s 50-day moving average is $267.01 and its 200-day moving average is $212.56. The stock has a market cap of $40.49 billion, a price-to-earnings ratio of 29.85, a PEG ratio of 2.18 and a beta of 1.16. IQVIA has a 52-week low of $154.50 and a 52-week high of $284.50.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion during the quarter, compared to analysts’ expectations of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. IQVIA’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter last year, the company posted $3.00 earnings per share. Sell-side analysts predict that IQVIA will post 11.53 EPS for the current year.

Insider Buying and Selling

In related news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the sale, the insider directly owned 24,989 shares of the company’s stock, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IQV. BlackRock Inc. acquired a new stake in shares of IQVIA during the second quarter worth $2,811,292,000. Canada Pension Plan Investment Board acquired a new position in shares of IQVIA in the second quarter valued at about $240,911,000. Bank of America Corp DE acquired a new position in shares of IQVIA in the second quarter valued at about $235,551,000. Legal & General Group Plc bought a new position in IQVIA during the second quarter worth about $211,342,000. Finally, Bank of New York Mellon Corp bought a new position in IQVIA during the second quarter worth about $180,296,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Further Reading

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.